Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) EBIT (2020 - 2025)

Historic EBIT for Agilon Health (AGL) over the last 6 years, with Q3 2025 value amounting to -$131.3 million.

  • Agilon Health's EBIT rose 167.33% to -$131.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$377.5 million, marking a year-over-year decrease of 837.77%. This contributed to the annual value of -$292.1 million for FY2024, which is 2584.6% down from last year.
  • As of Q3 2025, Agilon Health's EBIT stood at -$131.3 million, which was up 167.33% from -$116.0 million recorded in Q2 2025.
  • Over the past 5 years, Agilon Health's EBIT peaked at $417000.0 during Q1 2023, and registered a low of -$298.4 million during Q2 2021.
  • Moreover, its 5-year median value for EBIT was -$35.6 million (2021), whereas its average is -$66.9 million.
  • As far as peak fluctuations go, Agilon Health's EBIT plummeted by 2373091.05% in 2021, and later skyrocketed by 15612.38% in 2023.
  • Over the past 5 years, Agilon Health's EBIT (Quarter) stood at -$26.2 million in 2021, then crashed by 106.65% to -$54.1 million in 2022, then crashed by 203.89% to -$164.3 million in 2023, then surged by 34.21% to -$108.1 million in 2024, then decreased by 21.44% to -$131.3 million in 2025.
  • Its EBIT was -$131.3 million in Q3 2025, compared to -$116.0 million in Q2 2025 and -$22.1 million in Q1 2025.